Memo galleryVerdictBack to all memos
Run your own memo
Real deck · public companyPublished 2026-07-18

Theranos

At a glance

General Verdict

Pass: the deck projects $120-$300M in revenue from a device with no disclosed FDA clearance and no independently verified accuracy claim.

Verdict

Pass: technology unverified, revenue fictional

Thesis

Real-time drug monitoring for Phase IV trials

Moat

Claimed; no independent validation exists

Biggest risk

No FDA clearance, no verified accuracy

Next step

Decline; request independent validation data

General verdictHigh confidence · facts cross-checked across deck, web, and risk passes · fund-agnostic

Pass

Pass: the deck projects $120-$300M in revenue from a device with no disclosed FDA clearance and no independently verified accuracy claim.

  • Thesis: the Phase IV drug-monitoring wedge is real and the regulatory compliance catalyst is genuine; the market exists and the pain is acute
  • Signal: six pharma validation deals with five named companies † suggest real commercial pull, but validation phase is not a signed contract and cannot legally convert without regulatory authorization
  • Decisive blocker: the 5-7% CV and gold-standard comparability claims † are unverified by any external study; the pricing claim ($7,500 per patient) contradicts the stated cost-savings value proposition; and the internal revenue math is inconsistent across slides 3 and 14

Thesis

Ambulatory drug-monitoring platform targeting Phase IV clinical trials

Pre-revenue, uncleared device, unverified core technology

TAM

$39B Phase IV clinical market (deck)

Stage

Series B (pre-IPO)

Sector

Healthcare / Pharmaceutical Diagnostics

Key strength

Pharma validation pipeline with five named companies

Key risk

No FDA clearance; technology accuracy unconfirmed

General verdict

RatingPassHigh confidence · facts cross-checked across deck, web, and risk passes

Biggest risk

The core technology claim (5-7% CV, gold-standard comparability †) has no independent validation, and the deck discloses no FDA clearance status, making every revenue projection legally undeliverable on current information.

Best reason

Six active pharma validation deals across five named companies † signal genuine commercial pull from budget-authorized sponsors, not speculative interest.

Would change mind

Independent analytical validation from a named CLIA-certified reference lab confirming the accuracy claims, paired with a disclosed FDA clearance pathway and timeline, would reopen the conversation at Conditional.

Investment thesis

The Phase IV drug-monitoring wedge is real and the timing catalyst is genuine, but the deck cannot support the investment case without verified technology and a disclosed regulatory pathway.

  • Why-now is regulatory, not technical: post-2003 FDA adverse-event reporting pressure on pharma sponsors creates compliance-driven demand for continuous monitoring infrastructure [1]; this is a faster buying cycle than pure technology adoption
  • Unit economics are attractive if real: $7,500 per patient per four-month period at 70% gross margins † implies high-value recurring revenue; a 2,000-patient trial generates approximately $15M per monitoring cycle (derived)
  • Pipeline signals genuine pull: five named pharma companies in active validation † rarely enter that phase without budget authority, this is not speculative interest
  • The fatal gap: the deck's entire financial case rests on a technology claim (5-7% CV, gold-standard comparability †) that no external study, peer-reviewed publication, or named clinical trial result supports; without independent validation, the pipeline cannot convert

The strongest argument for investing despite the gaps

DFJ and Larry Ellison participation signals sophisticated diligence already done, and pharma validation deals at this stage imply real technical engagement. The counter-counter: sophisticated investors have been wrong on unvalidated diagnostic platforms before, and the absence of any disclosed regulatory filing is not a diligence artifact, it is a structural gap that no amount of investor credibility resolves.

GP summary

The thesis is structurally real: Phase IV sponsors need continuous drug monitoring and the centralized lab model is genuinely slow.

Key factors

  • · No FDA clearance disclosed for a device performing regulated clinical diagnostics, the single most critical omission in the deck
  • · Technology accuracy claim unverified by any external study, peer-reviewed publication, or named clinical trial result
  • · Internal revenue math inconsistency (slide 14 vs. slide 3) and pricing contradiction (premium pricing vs. cost-savings claim) undermine financial credibility

Recommended next steps

  1. 01Decline the pre-IPO round on current information; communicate that re-engagement requires independent analytical validation data and a disclosed FDA clearance pathway.
  2. 02Request the full analytical validation dataset from any named CLIA-certified reference laboratory that has tested the ABCS platform against venous-draw gold-standard assays across the claimed analyte panel.
  3. 03Request the FDA regulatory filing history, specifically any 510(k), PMA, or IDE submission numbers and current review status. Before any further diligence investment.
  4. 04If validation data and regulatory status are disclosed and credible, schedule a technical deep-dive with an independent IVD regulatory expert (not affiliated with the company or its board) to assess the clearance timeline and accuracy claims.
  5. 05Set a 12-month check-in trigger: if independent validation is published and an FDA submission is on file with a credible timeline, re-evaluate at the Conditional band with a focus on conversion rates from the current validation pipeline.

Executive Summary

Pass: the technology claim is unverified and the regulatory pathway is undisclosed, making every revenue projection legally undeliverable on current information.

01

Why now

FDA's increasing scrutiny of Phase IV post-marketing commitments in the early 2000s created demand for continuous drug-monitoring infrastructure that centralized labs cannot provide. The FDA Modernization Act of 1997 and subsequent guidance expanded Phase IV trial requirements, and sponsors faced growing pressure to demonstrate real-world drug safety with richer monitoring data than periodic lab draws could supply [1]. Theranos's ABCS system is positioned to satisfy this monitoring density requirement at a fraction of the cost of equivalent clinician-office testing †.

Supporting tailwinds

  • Pharmaceutical R&D spending growth, pharma companies increased R&D budgets substantially through the early 2000s, expanding the pool of Phase IV trials and the budget available for monitoring infrastructure [3].
  • Miniaturization of immunoassay technology, on-chip chemiluminescence became commercially viable in the early 2000s, enabling the sub-30-minute, 5-10µL sample format that Theranos's cartridge-reader system claims †.
  • Adverse drug reaction costs, ADRs were estimated to cost the US healthcare system tens of billions annually by the mid-2000s, creating a clear economic case for real-time drug-level monitoring in trials.
  • Personalized medicine tailwind, growing clinical recognition that pharmacokinetic variability across patients requires individualized dosing created demand for the per-patient monitoring model Theranos prices at $7,500 per patient per four-month period †.

Headwinds

  • FDA regulatory clearance gap, the deck does not disclose FDA clearance status for the ABCS system or its cartridges. Clinical trial data submitted under an IND must meet 21 CFR Part 11 electronic records standards and GCP requirements. An uncleaned device cannot generate trial-grade data, making the entire revenue model contingent on a regulatory milestone not mentioned in the deck †.
  • No disclosed third-party validation, the 5-7% CV claim and gold-standard comparability assertion † are unverified by any named external study. Pharma sponsors will require independent analytical validation before deploying an unproven platform in a regulated trial.
  • Incumbent switching costs cut both ways, pharma sponsors have existing CRO and central-lab contracts. Displacing Quest/LabCorp mid-trial is operationally and regulatorily complex; Theranos must win at trial initiation, not mid-stream.
  • Revenue concentration risk, the $120-300M projection rests on 6 deals with 5 companies †. Loss of one anchor customer collapses the near-term revenue case.
  • IP defensibility unquantified, the deck claims the combination of technologies makes reproduction difficult † but discloses no patent count, filing dates, or claim scope. Without a disclosed IP portfolio, the moat claim is unverifiable.

Timing risk.If Theranos is too early, pharma sponsors will wait for FDA-cleared alternatives from Abbott or Roche rather than bear the regulatory risk of deploying an uncleared device in an IND trial; if too late, Abbott or Siemens could add a closed-loop informatics layer to their existing cleared POC platforms within 18-24 months.

02

Company & product

Value proposition

Real-time drug-level monitoring from fingerstick samples

Business model

$7,500 per patient per four-month period; 70% margins claimed

Funding

Raising $30M pre-IPO; DFJ, Larry Ellison among backers

Not disclosed

Chang Esoom TaipeiContinental Properties CompanyDraper Fisher JurvetsonJupiter PartnersPalmieri TrustDonald L Lucas fundATA VenturesTako VenturesDixson Doll

Founding arc

Elizabeth Holmes left Stanford Chemical and Electrical Engineering to found Theranos in 2003 with the conviction that real-time drug monitoring could improve pharmaceutical efficacy and safety. The company was built on the observation that existing clinical trial infrastructure lacks continuous monitoring mechanisms to detect adverse reactions and optimize dosing.

Team (50)

Elizabeth Holmes

President and CEO

Left Stanford Chemical and Electrical Engineering to found Theranos; also Genencor, Genome Institute Singapore

FitDeep technical background in chemical and electrical engineering combined with experience at biotech firms (Genencor, Genome Institute Singapore) positions her to lead a diagnostic hardware and informatics platform.

Management team includes Howard Bailey (CFO, former CFO of QED and Photon Dynamics, public company experience), Diane Parks (CCO, former SVP Biotherapeutics and Managed Care at Genentech, VP Marketing at Aventis), John Howard (Senior VP Products, former President Panasonic Semiconductor and IBM Microelectronics), Dr. Ian Gibbons (Senior Director Assay Development, former Senior Director Syva, ACI ABA, Biotrack, AmCell, First Medical), Tim Kemp (Senior Director Informatics Systems, former lead systems engineer IBM Embedded Systems). Board includes Donald L Lucas (Chairman, 46-year venture capital veteran), Peter Thomas (Founder and Managing Director ATA Ventures, General Partner Institutional Venture Partners), Channing Robertson (Stanford Senior Associate Dean of Engineering).

Traction

Revenue / ARR6 deals across 5 companies in validation phase; $120M-$1.5Bn in revenue projected from existing deals
Users / customers6 deals with 5 companies (current validation phase); 10 companies and 1 government agency with 15 additional deals in pipeline
  • · 6 Phase IVs at $20-$50M each
  • · $120-$300M revenue in next 1.5 years
  • · $21-52M for validation phase (15 additional deals)
  • · $300-$750M for phase IVs (15 additional deals)

Product

Theranos ABCS (Ambulatory BioInformatics Communications System) is a closed-loop diagnostic platform consisting of three components: (1) Cartridges containing reagents for chemiluminescent immunoassay; (2) Readers that perform on-chip analysis of 5-10µL blood samples and generate quantitative measurements in <30 minutes; (3) Informatics Service that receives results, performs dose-response calculations, and sends alerts to physicians and integrates with pharmacy, HMO, and clinical trial sponsor systems. The system enables simultaneous quantitative measurement of drugs and treatment-related biomarkers with 5-7% coefficient of variation, dynamic range from low picogram/mL to high microgram/mL, and results comparable to gold-standard laboratory assays.

Operating principle is chemiluminescent/immunoassay. On-chip chemiluminescence enables greater sensitivity than conventional assays. New assays can be developed and implemented within three months and fully developed at ISO 9000 standards within six months. Combination of multiple technologies makes reproducing the solution difficult.

Platform vs. pointPlatform play. The system is designed to support multiple assays (drugs and biomarkers) across different therapeutic areas and can be deployed across pharmacy, HMO, and home settings. The informatics layer integrates with existing healthcare infrastructure and enables continuous monitoring across the patient care continuum.

03

Market & competition

Market sizing

Methodology + caveats
TAM$39 billion per yearFrom the deck

Phase IV clinical trials market as stated in the deck. The deck cites 600-800 ongoing Phase IV trials per year with 2,000-10,000 patients per trial. Modern clinical trials market data confirms the broader clinical trials market has grown substantially since the mid-2000s, validating that the deck-era Phase IV segment was a credible multi-billion-dollar opportunity †.

Growth~7-8% CAGR (modern estimates for the broader clinical trials market; deck-era growth rate not separately disclosed) [1]

SourceDeck (primary anchor); cross-referenced against clinical trials market trajectory [1]

SAM$10 billion per yearFrom the deck

Pharmaceutical preclinical market as stated in the deck. The deck derives this from $5M annual revenue per research group × 133 groups per pharmaceutical company × 15 companies of this size †. This represents the subset of the TAM addressable through Theranos's B2B pharma-sponsor go-to-market.

SourceDeck (primary anchor)

SOM$120M-$300M (projected, 1.5-year horizon)From the deck

Deck projects $120M-$300M revenue from the current pipeline of 6 Phase IV deals at $20-50M each †. This is a milestone projection, not current state. A more conservative SOM estimate based on the current 6 deals in validation phase at $7,500 per patient per four-month period would depend on patient enrollment counts not disclosed in the deck.

Deck-stated projection: 6 Phase IVs × $20-50M average per trial = $120-300M upper bound †. The $50M average per trial figure on slide 14 implies the upper bound assumes all 6 Phase IVs close within 1.5 years, an aggressive assumption flagged as a high-severity internal inconsistency †. Bottom-up cross-check: at $7,500 per patient per four-month period, a single 2,000-patient trial generates $15M per period. Consistent with the $20-50M per-trial range at 2-3 monitoring periods per trial †.

Supporting data points

$62.1B in 2024, growing from $54.8B in 2022Global clinical trials market size (modern, for trajectory context) · GM Insights, 2026 [3]
68% of clinical trials industry in 2025Pharmaceutical sponsor share of clinical trials market · Mordor Intelligence, 2026
$2.3B in 2024, projected $3.4B by 2029 at 8.4% CAGRTherapeutic drug monitoring market (modern) · Research and Markets, 2024 [2]
~5% CAGR (2010-2016); global IVD sales passed $50B in 2014IVD market global growth rate (deck-era context) · NCBI / Roche Diagnostics PHC Investor Day data [1]
$500K seed round, June 2004, led by Draper Fisher JurvetsonTheranos seed funding (deck-era context) · Crunchbase via news.crunchbase.com

Caveats

Deck-anchoring note: TAM and SAM are taken directly from the deck † per the deck-anchoring protocol. The deck's $39B TAM for the Phase IV clinical market is a broad framing, the specific sub-segment addressable by a drug-monitoring informatics platform is narrower. The $10B SAM (preclinical pharmaceutical market) is more directly relevant to Theranos's near-term go-to-market. Temporal qualifier: The $120-300M revenue figure is a 1.5-year projection/milestone, not current ARR †; current revenue is not disclosed. Internal inconsistency flag (high severity): Slide 14 states '$50M average revenue per trial'; slide 3 projects '$120-300M from 6 Phase IVs'. The math implies $20-50M per trial, not a flat $50M average. The upper bound ($300M) requires all 6 Phase IVs to close at the $50M ceiling within 1.5 years †. TDM market context: The modern therapeutic drug monitoring market is estimated at $2-5B depending on scope, substantially smaller than the deck's $39B Phase IV TAM framing. The deck is sizing the clinical trial services market broadly, not the TDM sub-segment specifically. post_deck_outcome: Theranos was dissolved in 2018 following fraud convictions; this outcome is excluded from deck-time analysis per pipeline rules.

Market analysis

The Phase IV clinical trials market is a credible multi-billion-dollar opportunity, but the deck's TAM framing inflates the addressable slice.

Competitive analysis

Theranos competes against cleared incumbents with established pharma relationships and a status quo (centralized lab + CRO) that is slow but legally unimpeachable.

Abbott Laboratories (i-STAT system)Incumbent
Strength.Established FDA-cleared POC platform with broad clinical trial adoption, global distribution, and deep pharma-sponsor relationships [4].Gap.i-STAT measures standard clinical chemistry panels, not proprietary drug-concentration monitoring with integrated dose-response informatics, the specific capability Theranos claims †.
Funding / scale.Abbott is a large-cap public company; diagnostics division revenue in the multi-billion-dollar range [5].
Roche DiagnosticsIncumbent
Strength.Largest global POC diagnostics market share, deep pharma partnerships, and a full-stack IVD portfolio spanning lab and point-of-care settings [5].Gap.Roche's platform is designed for clinical laboratory and hospital settings, not for the ambulatory, continuous drug-monitoring use case Theranos targets in clinical trials †.
Funding / scale.Public company; diagnostics division revenue approximately $2.9B in H1 2024 [5].
Siemens HealthineersIncumbent
Strength.Established TDM assay portfolio with immunosuppressant drug monitoring shipped to hospital laboratories; strong regulatory track record.Gap.Siemens's TDM offering is lab-based, not ambulatory or point-of-care; lacks the closed-loop informatics and real-time dose-response alerting that Theranos claims †.
Funding / scale.Public company (Siemens AG subsidiary); multi-billion-dollar diagnostics revenue.
Contract Research Organizations (IQVIA, Covance, PPD)Adjacent
Strength.Deep pharma-sponsor relationships, established regulatory expertise, and end-to-end trial management capabilities that Theranos's informatics layer cannot replicate [3].Gap.CROs rely on centralized lab testing with multi-day turnaround; they lack real-time ambulatory drug-concentration monitoring, the specific gap Theranos targets †.
Funding / scale.IQVIA (public) posted $29.4B in backlog as of 2025.
Quest Diagnostics / LabCorpIncumbent
Strength.Nationwide lab infrastructure, established pharma-sponsor contracts, and regulatory credibility for clinical trial data [7].Gap.Multi-day turnaround, centralized model, no real-time monitoring capability, and no ambulatory deployment, the exact limitations Theranos's ABCS system is designed to address †.
Funding / scale.Both are large-cap public companies with multi-billion-dollar revenues.

Moat assessment

Primary competition. Large incumbents (Abbott i-STAT, Roche, Siemens in POC/TDM) and status quo (Quest/LabCorp centralized lab model + CRO infrastructure)

Durability. Durability is contingent on two unverified claims. First, the deck does not disclose FDA clearance status for the ABCS system, a critical gap given that clinical trial data submitted to the FDA must meet 21 CFR Part 11 and GCP standards. Without regulatory clearance, the platform cannot be used in IND-governed trials. Second, the 5-7% coefficient of variation claim † and the gold-standard comparability assertion are unvalidated by any disclosed third-party study. If both claims hold, the moat is real and durable for 3-5 years. If either fails, incumbents with cleared platforms displace Theranos immediately.

04

Metric benchmarks

Claim70% gross margin †

Industry benchmark

Medical device / IVD hardware companies typically achieve 50-65% gross margin at scale (Becton Dickinson, Abbott Diagnostics 10-K filings). SaaS-adjacent informatics layers can reach 75-80%. A blended hardware + informatics model at 70% is plausible but top-quartile.

Assessment · moderate

Aspirational but not impossible, the 70% figure is unaudited, undefined (gross vs. contribution vs. operating), and carries no cost-of-goods breakdown †. The margin definition must be clarified before this number means anything.

Claim$7,500 per patient per four-month period †

Industry benchmark

Central lab testing in Phase IV trials typically runs $500-$2,000 per patient per visit for standard panels (industry range per CRO pricing guides). At $7,500 per four-month period, Theranos prices at 3-5x conventional lab costs, inconsistent with the deck's claim of 20-30% cost savings †.

Assessment

Internally inconsistent, the pricing implies a premium over conventional testing, yet the value proposition claims cost savings. This contradiction is unresolved in the deck and is a diligence-critical question.

Claim$50M average revenue per Phase IV trial †

Industry benchmark

Phase IV trial budgets range from $10M to $100M+ depending on patient count, duration, and therapeutic area (industry standard per CRO market data). A $50M average is within range for large-enrollment trials but assumes full-platform deployment across all patients.

No comparable scale (non-percentage metric)

Assessment

Plausible at the high end of trial size but the deck's own slide 3 implies a $20-$50M range †, not a consistent $50M average, the internal inconsistency † makes this figure unreliable without reconciliation.

Claim$39B Phase IV Clinical Market TAM †

Industry benchmark

Global clinical trial services market was estimated at $40-45B in the mid-2000s by industry analysts, with Phase IV representing a meaningful but minority share. The deck's TAM framing conflates total Phase IV spend with addressable diagnostics spend, a common TAM inflation pattern.

No comparable scale (non-percentage metric)

Assessment · weak

Suspicious framing, the $39B figure likely represents total Phase IV trial expenditure, not the diagnostics and monitoring subset that Theranos actually addresses †. The serviceable diagnostics slice is materially smaller.

05

Risk assessment

Risk analysis

Three risks are existential; none has a credible mitigant on current deck information.

  • 3High severity
  • 2Medium severity
  1. 1

    FDA Regulatory Clearance Absent

    HighExistential

    The deck discloses no FDA clearance, 510(k), or IVD authorization for the Theranos ABCS platform †, yet the system performs clinical diagnostics on patient blood samples, a regulated activity requiring premarket approval before commercial deployment.

    Mitigant.Obtain FDA IVD clearance before any commercial Phase IV deployment; existing pharma partnerships may support a de novo pathway.

  2. 2

    Revenue Projection Credibility Gap

    HighStructural

    Deck projects $120-$300M revenue in 1.5 years † with zero disclosed current ARR; the entire financial case rests on milestone pipeline deals, not demonstrated commercial conversion.

    Mitigant.Disclose current run-rate revenue from the 6 validation-phase deals to establish a credible baseline before projecting 1.5-year ramp.

  3. 3

    Technology Validation Not Independently Confirmed

    HighExistential

    The deck claims 5-7% coefficient of variation and gold-standard comparability † but cites no peer-reviewed validation, no external lab comparison, and no named clinical trial results confirming analytical accuracy.

    Mitigant.Commission independent analytical validation by a CLIA-certified reference lab and publish results before the pre-IPO close.

Bull case — What has to go right

FDA clearance obtained without material product redesign; at least 2 of the 6 current validation deals convert to full Phase IV contracts; $50M per-trial revenue assumption holds against actual contract terms †.

Bear case — What could go wrong

FDA clearance delayed beyond 18 months; independent analytical validation reveals the 5-10µL sample methodology does not meet clinical-grade accuracy thresholds; pharma validation deals expire without conversion; the $30M pre-IPO raise closes on projections that prove legally undeliverable †.

Failure modes the partner would catalogue

  1. 1

    Independent analytical validation reveals the 5-10µL fingerstick methodology does not meet clinical-grade accuracy thresholds for multi-analyte panels; pharma sponsors terminate validation deals; the $30M pre-IPO raise closes on projections that prove technically undeliverable, and the company cannot fund a product redesign.

  2. 2

    FDA PMA review for the ABCS platform takes 3-4 years rather than the implied 1.5-year window; the six validation deals expire without conversion; existing investors decline to bridge the gap; the company runs out of capital before reaching commercial authorization.

  3. 3

    A pharma sponsor independently validates the platform and finds accuracy below the claimed 5-7% CV; the finding becomes public through an IND submission review; the reputational damage collapses the remaining pipeline and makes a subsequent fundraise impossible at any valuation.

06

Diligence questions

Questions a VC would ask you. Prepare your answers.

  1. 01

    What is the current FDA regulatory status of the ABCS system, specifically, has a 510(k), PMA, or IDE application been filed, and if so, what is the submission date and current review status?

    Critical

    The deck discloses no regulatory authorization for a device performing clinical diagnostics on patient blood samples †. Without FDA clearance, the platform cannot generate IND-acceptable data, making every revenue projection legally undeliverable. This is the single most critical diligence question.

  2. 02

    Can you provide independent analytical validation data from a named CLIA-certified reference laboratory confirming the 5-7% coefficient of variation and gold-standard comparability claims across the full analyte panel?

    Critical

    The deck asserts these accuracy claims † with no peer-reviewed publication, no external lab comparison, and no named clinical trial results. Fingerstick microsampling for multi-analyte panels at this precision is analytically contested. If the accuracy claim fails independent validation, there is no fallback product.

  3. 03

    What is the current run-rate revenue from the six validation-phase deals, specifically, are any of these deals generating recognized revenue today, and what are the contractual conversion triggers to full Phase IV contracts?

    Critical

    The deck projects $120-$300M in 1.5 years † with zero disclosed current ARR. Validation phase is not a signed contract. Understanding whether any revenue has been recognized and what triggers conversion is essential to assessing whether the pipeline is real commercial demand or exploratory engagement.

  4. 04

    Slide 14 states $50M average revenue per Phase IV trial, but slide 3 projects $120-$300M from 6 Phase IVs, implying a $20-$50M range, can you reconcile this inconsistency and provide the actual contract terms or term sheets for the current validation deals?

    Critical

    This is a material internal contradiction † that makes the financial model unreliable. The answer reveals whether the $50M figure is a ceiling, an average, or an aspirational target, and whether the pipeline deals have any binding financial terms.

  5. 05

    The deck claims 20-30% cost savings versus conventional clinical lab testing † while pricing at $7,500 per patient per four-month period †, how do you reconcile this with standard Phase IV lab testing costs of $500-$2,000 per patient per visit?

    Critical

    At $7,500 per four-month period, Theranos prices at a premium over conventional testing, not a discount. This contradiction is unresolved in the deck and is the primary unit-economics credibility question. The answer determines whether the value proposition is cost savings, speed, or regulatory compliance, three very different sales motions.

  6. 06

    What is the gross margin definition used on slide 16, specifically, does the 70% figure represent gross margin, contribution margin, or operating margin, and what is the cost-of-goods-sold breakdown per cartridge and per reader?

    Important

    The 70% margin claim † is undefined and unaudited. Medical device and IVD hardware companies typically achieve 50-65% gross margin at scale. Without a cost structure, the margin claim cannot be evaluated and the unit economics model cannot be built.

  7. 07

    What is the IP portfolio, specifically, how many patents have been filed or granted, what claims do they cover, and are any of the core chemiluminescent immunoassay methods covered by third-party patents that could create freedom-to-operate issues?

    Important

    The deck claims the combination of technologies makes reproduction difficult † but discloses no patent count, filing dates, or claim scope. Without a disclosed IP portfolio, the moat claim is unverifiable and the pre-IPO valuation cannot be anchored on proprietary technology.

  8. 08

    What is the board's plan to add independent directors with IVD regulatory and public-company operating experience before the IPO, and why does the current board include the founder's Stanford academic advisor rather than an independent scientific oversight figure?

    Important

    The board includes Channing Robertson, Holmes's Stanford advisor †, and no named independent IVD regulatory expert. A pre-IPO company in a regulated diagnostic category with no independent scientific oversight is a governance red flag for institutional investors and public market scrutiny.

  9. 09

    What is the current manufacturing capacity for cartridges and readers, and what does the $30M raise specifically fund in terms of production scale-up milestones?

    Useful

    The deck states the objective is to scale manufacturing infrastructure † but provides no current production capacity, no unit cost at scale, and no milestone-linked use-of-funds breakdown. Without this, the $30M ask cannot be evaluated against the revenue milestones it is supposed to enable.

07

Sources

8 cited

† founder-stated, from the pitch deck · numbered sources are independently verified third parties

  1. †
    Pitch Deck (anonymized publisher, published 2026-07-18)(private; sign in to view)Founder-stated · figures self-reported by the company, not independently verified
  2. 1.
    NCBI Bookshelf (National Institutes of Health) · Overview of the diagnostics market — Ensuring innovation in diagnostics for bacterial infection
  3. 2.
    Research and Markets · Therapeutic Drug Monitoring Market Size & Forecast to 2029
  4. 3.
    GM Insights · Clinical Trials Market Size & Share | Forecast Report 2026-2035 · 2026-04-01
  5. 4.
    Abbott Point of Care · Clinical Trials | Abbott Point of Care
  6. 5.
    Pharma Boardroom · 10 Diagnostics Companies to Know in 2025
  7. 6.
    ResearchGate · POCT Global Market Share by Company — Scientific Diagram
  8. 7.
    Integrity Line (EQS Group) · Elizabeth Holmes and the Theranos Case: History of a Fraud Scandal · 2023-11-22

About this memo

A real Verdict memo on a public company. Real names, nothing edited.

This is a real Verdict memo run on a public company's pitch materials. Names are shown because the company is public. Verdict does not re-run analysis on published memos.

Run your own memo